Phaseline

Companies › Volastra Therapeutics

Volastra Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VLS-1488–Phase 1Advanced Solid TumorDec 2026
Sovilnesib–Phase 1High Grade Serous Adenocarcinoma of OvaryNov 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05902988VLS-1488Phase 1Advanced Solid TumorOncologyDec 2026
NCT06084416SovilnesibPhase 1High Grade Serous Adenocarcinoma of OvaryOncologyNov 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.